Membrane Oxygenators Market Size & Share 2026-2035

Membrane Oxygenators Size

The membrane oxygenators market is estimated at USD 133.8 million in 2025 and is projected to reach USD 167.5 million by 2035, expanding at an approximately 2.4% CAGR from 2026 to 2035.

This follows an approximately 1.6% CAGR during 2022-2024. Demand is rooted in high-acuity extracorporeal support, where the oxygenator performs gas exchange outside the body during cardiopulmonary bypass and extracorporeal membrane oxygenation (ECMO).^{[1]PMC/Springer - Evolutions of extracorporeal membrane oxygenator (ECMO), March 2023 - pmc.ncbi.nlm.nih.gov}

Hollow fiber and flat sheet designs serve different clinical and procurement requirements. Hollow fiber platforms, particularly those using polymethylpentene (PMP) membranes, support longer-duration ECMO because the membrane's dense outer layer limits plasma leakage associated with earlier microporous designs. ^{[2]PMC/ASAIO Journal - Extracorporeal Life Support Organization Registry International Report 2022: 100,000 Survivors, 2024 - pmc.ncbi.nlm.nih.gov}Flat sheet devices remain relevant in shorter-duration extracorporeal circulation and selected specialized circuits, but their lower projected growth reflects the clinical shift toward long-duration ECMO-capable hollow fiber systems.

Respiratory failure, cardiac support, and extracorporeal cardiopulmonary resuscitation (ECPR) define the principal demand pool. Registry reporting shows the expansion of adult ECMO activity and reporting-center participation over the past decade, establishing a larger installed base of programs that require recurring disposable circuit components. ECPR has particular strategic importance because comparative evidence has associated it with improved survival and neurological outcomes versus conventional CPR in selected cardiac-arrest settings.

The forecast CAGR of approximately 2.4%, compared with approximately 1.6% during 2022-2024, indicates measured acceleration rather than a return to pandemic-era utilization. ECPR protocol development, cardiac shock management, and new ECMO-center formation provide incremental demand, while regulatory qualification and the total cost of ECMO limit adoption outside advanced hospitals. The commercial advantage therefore rests with suppliers that can support both long-duration ECMO requirements and lower-cost cardiac-surgery procurement models.

Key Drivers

Rising Cardiovascular Disease Prevalence

Cardiovascular disease creates the largest long-term clinical base for cardiac ECMO and oxygenator use in cardiogenic shock, post-cardiotomy support, and bridge-to-decision care. The World Health Organization estimates that cardiovascular diseases caused 19.8 million deaths in 2022, equivalent to approximately 32% of global deaths. A 2025 global burden assessment reported 626 million prevalent cardiovascular disease cases and 19.2 million deaths in 2023, demonstrating the scale of patients who may progress to severe cardiac decompensation.^{[3]The Lancet Respiratory Medicine - Extracorporeal cardiopulmonary resuscitation versus conventional cardiopulmonary resuscitation in adults with cardiac arrest: A comparative meta-analysis and trial sequential analysis, 2023 - thelancet.com}

The demand effect is indirect but durable. Rising disease prevalence does not translate automatically into ECMO utilization; it increases the number of patients reaching tertiary cardiac programs, where oxygenators are used when conventional medical and mechanical support is insufficient. This favors suppliers with adult cardiac portfolios and established hospital relationships.

Growing Demand for Extracorporeal Membrane Oxygenation

ECMO program expansion converts clinical capability into recurring oxygenator demand. The ELSO Registry reported 154,568 ECMO runs from 2009 to 2022 across 780 reporting centers, with adult annual runs increasing from 851 in 2009 to 17,975 in 2021. A longer support episode may also require circuit-component replacement, making utilization intensity as important as the number of active centers.

The commercial consequence is a preference for products that integrate reliably with established pumps, tubing sets, monitoring systems, and local perfusion workflows. Once an ECMO program standardizes a circuit configuration, the cost of switching includes retraining, protocol revision, and supply-continuity risk rather than simply the price of an individual oxygenator.

High Incidence of Acute Respiratory Distress Syndrome

ARDS remains a substantial demand substrate for venovenous ECMO when lung-protective ventilation cannot sustain gas exchange. The LungSAFE study found that ARDS represented 10.4% of ICU admissions and 23.4% of mechanically ventilated patients across its international cohort.^{[4]World Health Organization - Cardiovascular diseases (CVDs) - who.int} U.S. estimates place ARDS incidence at 64.2-78.9 cases per 100,000 person-years, while sepsis, pneumonia, and shock are important associated risk factors.

ARDS does not create uniform oxygenator demand because ECMO is reserved for a narrow, severe cohort. Nevertheless, its prevalence supports the respiratory segment's base demand and creates a need for durable devices that can sustain prolonged respiratory support without compromising gas-transfer performance.

Rise in Organ Transplant Procedures

Growing transplant activity supports demand through intraoperative cardiopulmonary support and management of post-transplant graft dysfunction. The Global Observatory on Donation and Transplantation reported 173,727 solid-organ transplants worldwide in 2024, including 10,287 heart transplants and 8,236 lung transplants. Heart and lung procedures are particularly relevant because their perioperative pathways may require extracorporeal circulation or temporary ECMO.

Transplant growth is concentrated in specialized centers, which makes it commercially valuable despite its limited absolute volume. Suppliers that can meet the technical requirements of cardiac surgery, post-operative rescue, and pediatric transplantation can participate in several high-acuity purchasing categories within the same institution. ^{[5]Journal of the American College of Cardiology/IHME - Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023, 2025 - jacc.org}

Surging Applications in Pediatric and Neonatal Care

Neonatal and pediatric ECMO requires low-priming-volume circuits and age-specific device configurations. ELSO data show pediatric annual runs increased from 1,154 in 2009 to 2,394 in 2021, while neonatal respiratory ECMO survival to hospital discharge was 68.5%. Pediatric ECMO outcomes in South Korea also improved over a 10-year observation period, indicating the maturation of specialized programs.

These applications remain smaller than adult use, but they are technically demanding and less substitutable. Product selection depends on priming volume, flow range, blood-contacting surface design, and compatibility with neonatal anticoagulation protocols. This creates a defensible differentiation opportunity for suppliers able to maintain dedicated neonatal and pediatric product lines. ^{[6]JAMA - Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries, 2016 - pubmed.ncbi.nlm.nih.gov}

Key Restraints

Strict Regulatory Requirements

Regulatory classification constrains product launches, modifications, and geographic expansion. The U.S. Food and Drug Administration has differentiated oxygenator devices used in extracorporeal circulation according to intended duration and use, while its 2023 safety communication highlighted the operational consequences of device-quality failures for hospitals and manufacturers . The Novalung ultimate kit received FDA 510(k) clearance under K232926 in April 2024, illustrating the importance of formal regulatory authorization for integrated extracorporeal systems.

The barrier extends beyond initial clearance. Oxygenator manufacturers must demonstrate biocompatibility, performance consistency, packaging integrity, and post-market control. The Getinge Quadrox action discussed by the FDA showed that a packaging-related concern can interrupt supply, force hospitals to qualify substitutes, and impose costly remediation on a supplier. Regulatory rigor therefore protects established, cleared platforms but slows product-refresh cycles and raises the threshold for new competitors.

High Costs of Advanced Oxygenators

The economic constraint is the full ECMO episode rather than the oxygenator alone. U.S. pandemic-period data reported mean ECMO hospitalization costs of USD 967,647 and an average length of stay of 26 days, reflecting staffing, intensive care, anticoagulation, and other resource requirements in addition to disposable components. ^{[7]NIH/NCBI StatPearls - Acute Respiratory Distress Syndrome - ncbi.nlm.nih.gov} Hospitals in markets with limited reimbursement may therefore defer ECMO program investment even where clinical need is present.

Reimbursement can either absorb or amplify this friction. Germany's ZE2024-03 framework recognizes ECMO and percutaneous extracorporeal lung assist as reimbursable add-on services, while other systems rely on less predictable funding arrangements. In China, lower-cost domestic systems have helped reduce the reported cost of ECMO relative to Western settings, but this also increases pricing pressure for multinational suppliers. The result is a segmented market: premium features are more readily monetized in reimbursement-supported accounts, whereas price and local access determine adoption in newly developing programs.

Regulatory demands and episode-level economics reinforce the market's concentration around tertiary institutions. The most attractive growth opportunities are consequently not generic volume gains; they are new program openings, higher use at qualified centers, and replacement demand from circuit standardization. Suppliers that pair regulatory depth with cost-conscious configurations are better positioned to address both mature reimbursement markets and emerging ECMO systems.

Membrane Oxygenators Segment Analysis

By Type

Hollow Fiber Membrane Oxygenators

Hollow fiber membrane oxygenators generated USD 80.2 million in 2025, representing approximately 59.9% of market revenue, and are projected to reach USD 103.9 million by 2035 at an approximately 2.7% CAGR. Their growth premium reflects their central role in ECMO, where PMP hollow fiber membranes support extended gas exchange and are compatible with advanced blood-contacting surface treatments.

Surface modification is becoming an important non-price differentiator. Research on nitric oxide-releasing selenium-phosphorylcholine coatings has demonstrated antithrombotic and anti-inflammatory potential in ECMO-related applications. Separate research on phosphorylcholine-heparin composite coatings reported improved hemocompatibility indicators for artificial lung membranes. These developments remain research-stage evidence rather than proof of commercial performance, but they explain why coating technology is strategically relevant to premium oxygenator platforms.

Flat Sheet Membrane Oxygenators

Flat sheet membrane oxygenators accounted for USD 53.6 million in 2025 and are forecast to reach USD 63.7 million by 2035, at an approximately 1.8% CAGR. Their slower growth is consistent with the migration of prolonged support toward hollow fiber systems. Flat sheet designs retain demand in selected short-duration cardiac-surgery and specialized extracorporeal applications, where operational familiarity and lower system complexity can outweigh long-duration performance requirements.

By Application

Respiratory

The respiratory segment is valued at USD 61.0 million in 2025, representing approximately 45.6% of market revenue, and is expected to reach USD 74.4 million by 2035 at an approximately 2.1% CAGR. Respiratory failure is the largest respiratory subsegment, rising from USD 22.0 million to USD 27.8 million at an approximately 2.4% CAGR. Pulmonary embolism is projected to increase from USD 17.4 million to USD 21.4 million at an approximately 2.2% CAGR.

ARDS is forecast to rise from USD 13.3 million in 2025 to USD 15.8 million in 2035, at an approximately 1.8% CAGR. Pneumonia grows from USD 8.3 million to USD 9.5 million, at an approximately 1.4% CAGR. The lower growth rates for ARDS and pneumonia reflect selective ECMO use: oxygenators are deployed after conventional management fails, not across the complete respiratory-disease population.

Cardiac

Cardiac applications are estimated at USD 45.5 million in 2025 and are projected to reach USD 56.6 million by 2035, at an approximately 2.3% CAGR. Decompensated cardiomyopathy is the largest cardiac subsegment, increasing from USD 15.7 million to USD 19.0 million at an approximately 2.1% CAGR. Acute myocardial infarction is the fastest-growing cardiac subsegment, advancing from USD 12.6 million to USD 16.4 million at an approximately 2.7% CAGR.

Cardiogenic shock is projected to expand from USD 10.0 million to USD 12.7 million at an approximately 2.5% CAGR. Post-transplant complications increase from USD 5.1 million to USD 6.1 million at an approximately 1.8% CAGR, and myocarditis rises from USD 2.2 million to USD 2.4 million at an approximately 1.1% CAGR. Evidence reviews of venoarterial ECMO continue to emphasize the need to align patient selection and timing with the clinical context, limiting indiscriminate adoption even in high-burden cardiac indications.

ECPR

ECPR is projected to be the fastest-growing application, increasing from USD 27.3 million in 2025 to USD 36.5 million in 2035 at an approximately 3.0% CAGR. A comparative meta-analysis found lower in-hospital mortality associated with ECPR than conventional CPR, including in the in-hospital cardiac-arrest subgroup, while also reporting better long-term neurological outcomes.

The practical implication is concentration rather than universal decentralization. ECPR requires rapid cannulation, trained teams, and tightly coordinated emergency workflows. Higher-volume centers are more likely to convert clinical evidence into repeatable protocols, making rapid-deployment, ECMO-rated oxygenator systems particularly relevant in tertiary and quaternary hospitals. ^{[8]PubMed - National incidence rates for acute respiratory distress syndrome and ARDS cause-specific factors in the United States, 2006-2014, 2018 - pubmed.ncbi.nlm.nih.gov}

By Age Group

Adults

Adults account for USD 85.5 million in 2025, or approximately 63.9% of market revenue, and are expected to reach USD 112.1 million by 2035 at an approximately 2.8% CAGR. Adult dominance reflects the prevalence of cardiogenic shock, acute myocardial infarction, respiratory failure, and cardiac arrest within the adult population. The segment also benefits from the growth of ECPR, which is largely concentrated in adult emergency and cardiac-care pathways.

Neonates

The neonatal segment is valued at USD 31.4 million in 2025 and is forecast to reach USD 36.6 million by 2035, at an approximately 1.6% CAGR. Neonatal applications require specialized systems with low priming volumes and controlled flow ranges. A 2023 trial evaluated an infant and pediatric oxygenator in surgical neonates receiving ECMO, illustrating the highly specific clinical and technical requirements of this patient group.

Pediatrics

Pediatrics account for USD 17.0 million in 2025 and are projected to reach USD 18.9 million by 2035, at an approximately 1.2% CAGR. The smaller growth rate reflects a narrower patient base and mature referral pathways in established markets. However, pediatric platforms remain commercially significant because clinical acceptance depends on dedicated configurations rather than scaled-down adult products.

By End Use

Hospitals

Hospitals represent the largest end-use segment at USD 59.0 million in 2025, or approximately 44.1% of revenue, and are projected to reach USD 77.8 million by 2035 at an approximately 2.9% CAGR. ECMO delivery is embedded in hospital ICUs, operating rooms, and referral networks. A European geospatial analysis found that timely access to extracorporeal life support remains uneven across participating countries, indicating that hospital-based capacity expansion can create new demand where access gaps persist.

Hospital procurement is increasingly shaped by system agreements. Fresenius Medical Care's November 2024 agreement with Premier extended negotiated access to the Novalung ECMO System across Premier's U.S. member network. Such arrangements strengthen suppliers that can offer regulatory-cleared systems, consumable continuity, clinical support, and contracting capability.

Ambulatory Surgical Centers

Ambulatory surgical centers account for USD 45.0 million in 2025 and are forecast to reach USD 54.7 million by 2035, at an approximately 2.1% CAGR. Their demand is linked primarily to shorter-duration perfusion and cardiac-surgery workflows rather than prolonged ECMO. Procurement emphasis is therefore more likely to favor cost, routine compatibility, and procedure-specific configuration.

Other End Users

Other end users generated USD 29.8 million in 2025 and are projected to reach USD 35.0 million by 2035, at an approximately 1.7% CAGR. This category includes specialized transport, research, and extracorporeal blood-management settings. Its growth remains moderate because these applications do not offer the recurring, protocol-driven demand profile of hospital ECMO programs. ^{[9]PubMed/Transplantation - Organ Donation and Transplantation Worldwide: The Global Observatory on Donation and Transplantation 2024, 2025 - pmc.ncbi.nlm.nih.gov}

ECPR's approximately 3.0% CAGR is more consequential than its absolute size alone suggests. It directs demand toward institutions that can execute rapid response protocols and toward suppliers with deployment-ready, long-duration systems. By contrast, the slower pneumonia, pediatric, and flat sheet trajectories preserve a meaningful role for cost-effective and specialized configurations. Portfolio breadth across adult ECMO, neonatal care, and surgical perfusion is therefore a more durable competitive advantage than exposure to a single procedure category.

Membrane Oxygenators Regional Analysis

North America

North America is estimated at USD 47.2 million in 2025, representing approximately 35.2% of global revenue, and is projected to reach USD 54.8 million by 2035 at an approximately 1.6% CAGR. The U.S. market increases from USD 44.4 million to USD 51.1 million at an approximately 1.5% CAGR, while Canada rises from USD 2.7 million to USD 3.7 million at an approximately 3.1% CAGR.

The region's slower growth reflects market maturity rather than weak demand. Established ECMO centers, reimbursement pathways, and FDA-cleared product availability support high utilization, but further growth depends more on procedure intensity and protocol expansion than on widespread formation of new programs. The FDA's Quadrox communication also demonstrated why supply assurance has become a procurement consideration alongside clinical familiarity.

Europe

Europe is forecast to expand from USD 36.8 million in 2025 to USD 45.0 million in 2035, at an approximately 2.1% CAGR. Germany, France, the UK, Spain, Italy, and the Netherlands form the covered market base. Reimbursement structures, established cardiac programs, and regional ECMO networks support demand, although access remains uneven across the continent.

Germany's ECMO and PECLA add-on reimbursement framework provides a clearer funding mechanism than many other markets. Across Europe, however, center concentration can constrain the number of purchasing sites even as it preserves clinical expertise and procedure quality. Suppliers must therefore balance national tender access with clinical-service capability at high-volume referral centers.

Asia Pacific

Asia Pacific is projected to be the fastest-growing region, advancing from USD 35.9 million in 2025 to USD 49.3 million in 2035 at an approximately 3.3% CAGR. China, Japan, India, Australia, and South Korea are included in the regional scope. The growth mechanism is expansion of ECMO availability, particularly in China, rather than only higher utilization at mature centers.

China's reported expansion into additional hospitals and the emergence of domestic ECMO products are reducing access barriers, but they also introduce material price competition. Japan retains deep technical experience in membrane oxygenator development, while South Korea's improving pediatric ECMO outcomes indicate expanding clinical maturity. India and Australia contribute through the development of tertiary critical-care and transplant capacity.

Latin America

Latin America is estimated at USD 8.9 million in 2025 and is projected to reach USD 11.7 million by 2035, at an approximately 2.9% CAGR. Brazil and Mexico anchor demand, with Argentina contributing through tertiary hospital activity. Growth begins from a smaller installed base and is limited by device-import exposure, uneven reimbursement, and shortages of specialized personnel.

The regional opportunity is therefore selective. Local distribution capability and price discipline matter more than broad national demand estimates, because hospitals must be able to fund the full ECMO pathway before oxygenator volume can scale consistently.

Middle East and Africa

The Middle East and Africa market is projected to grow from USD 5.1 million in 2025 to USD 6.7 million in 2035, at an approximately 2.9% CAGR. South Africa, Saudi Arabia, and the UAE represent the covered markets. Demand is concentrated in advanced cardiac, transplant, and critical-care institutions, with expansion limited by training availability and funding conditions outside a small number of referral centers.

Growth depends on institutional capability development rather than routine adoption. Suppliers entering the region must account for distributor support, clinical training, product availability, and the ability of individual hospitals to sustain consumable inventory for infrequent but high-cost cases.

Asia Pacific's projected approximately 3.3% CAGR makes it the principal regional expansion opportunity, but the pathway is not equivalent to premium-market growth in North America. China's domestic ECMO supply development can broaden access while challenging established suppliers' pricing power. Successful market approaches will consequently differ: premium clinical differentiation and contract performance are critical in mature systems, whereas affordability, local service, and training support are central in developing ECMO networks. ^{[10]Journal of Korean Medical Science - Pediatric Extracorporeal Membrane Oxygenation in Korea, 2024 - jkms.org}

Membrane Oxygenators Share & Competitive Landscape

Competition is defined by regulatory clearance, circuit integration, clinical familiarity, surface technology, and the ability to maintain supply to high-acuity programs. The approved company scope comprises Abbott, BRAILE, chalice, CytoSorbents, EUROSETS, Fresenius, GETINGE, LivaNova, Medtronic, MicroPort, NIPRO, PrecisionMedical, RECTUS MEDICAL, TERUMO, and XENIOS.

Abbott participates in pediatric-focused extracorporeal support applications. Its relevance is reinforced by clinical evaluation of an infant and pediatric oxygenator in neonatal ECMO settings.

BRAILE serves adult cardiac and respiratory applications, with particular relevance to Brazilian hospital and cardiac-surgery procurement.

chalice markets PMP hollow fiber oxygenator configurations for adult and neonatal cardiac use. The FDA cleared its CMO8 Adult PMP Oxygenator with Tubing Pack under K231414 in November 2023.

CytoSorbents participates through blood-purification technology that can be used alongside extracorporeal circuits, addressing inflammatory-mediator management rather than conventional oxygenation alone.

EUROSETS offers ECMO-focused oxygenator systems across adult, neonatal, and pediatric care. Its AMG PMP oxygenator has been included in comparative oxygenator dysfunction analysis.

Fresenius markets the Novalung ECMO system. Its Premier agreement provides a route to negotiated access across U.S. hospital members, strengthening its hospital-channel position.

Recent Industry Developments

Fresenius Medical Care-Premier Agreement: On November 19, 2024, Fresenius Medical Care announced a group purchasing agreement with Premier for the Novalung ECMO System for Mechanical Circulatory Support. The agreement provides negotiated access across Premier's member network and reinforces the importance of purchasing-group relationships in U.S. hospital adoption.

Getinge Quadrox FDA Communication: The FDA issued a June 2023 letter to healthcare providers concerning oxygenator devices used for extracorporeal circulation after Getinge/Maquet actions related to potentially compromised packaging sterility. The agency advised providers not to use affected devices for new procedures and to consider alternatives. The event highlighted the exposure created by reliance on a limited number of qualified oxygenator suppliers.

Novalung Ultimate Kit Clearance:The FDA cleared the Novalung ultimate kit under 510(k) K232926 in April 2024. The clearance is relevant because it covers a pre-connected extracorporeal circuit configuration designed for respiratory and cardiopulmonary support, including specified adult indications.

Chalice CMO8 Oxygenator Clearance: Chalice Medical received FDA 510(k) clearance for the CMO8 Adult PMP Oxygenator with Tubing Pack under K231414 in November 2023. The clearance demonstrates continuing product activity in the U.S. oxygenator market.

Advances in Surface-Coating Research: Peer-reviewed studies published in 2023 and 2025 examined phosphorylcholine-based, heparin-containing, and nitric oxide-releasing surface strategies intended to improve blood compatibility in artificial lung membranes. These findings are pre-commercial research, but they indicate that reduced thrombosis and inflammatory activation remain central development objectives for next-generation ECMO oxygenators.